Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 82.83% |
| 2 | Healthcare | 3.13% |
| 3 | Technology | 2.97% |
| 4 | Financials | 2.19% |
| 5 | Consumer Discretionary | 2.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
HYZNW
14326
DELISTED
Hyzon Motors Inc. Warrants
HYZNW
| $216 | ﹤0.01% |
45,895
-47,260
| -51% | -$808 |
2023 Q4
4 quarters
|
|
14327
iShares US Telecommunications ETF
IYZ
$1.1B
| $215 | ﹤0.01% |
8
-40,674
| -100% | -$1.09M |
2024 Q1
3 quarters
|
|
14328
CALL
Spero Therapeutics
SPRO
$69.3M
| $206 | ﹤0.01% |
200
| – | – |
2024 Q2
2 quarters
|
|
|
14329
PUT
Spero Therapeutics
SPRO
$69.3M
| $206 | ﹤0.01% |
200
| – | – |
2024 Q2
2 quarters
|
|
14330
PUT
IGC Pharma
IGC
$28.4M
| $202 | ﹤0.01% |
600
-600
| -50% | -$225 |
2024 Q2
2 quarters
|
|
14331
PUT
Aware
AWRE
$24M
| $195 | ﹤0.01% |
100
-100
| -50% | -$171 |
2024 Q3
1 quarter
|
|
14332
PUT
Ovid Therapeutics
OVID
$465M
| $187 | ﹤0.01% |
200
-300
| -60% | -$336 |
2024 Q1
3 quarters
|
|
|
STKH
14333
PUT
Steakholder Foods
STKH
$724K
| $171 | ﹤0.01% |
1
-2
| -67% | -$578 |
2024 Q3
1 quarter
|
|
14334
ProShares UltraPro Short 20+ Year Treasury
TTT
$28.8M
| $160 | ﹤0.01% |
2
-3,173
| -100% | -$226K |
2024 Q3
1 quarter
|
|
|
RAPT
14335
DELISTED
RAPT Therapeutics
RAPT
| $158 | ﹤0.01% |
+13
| New | +$165 |
2024 Q4
0 quarters
|
|
|
XOSWW
14336
DELISTED
Xos Inc Warrants
XOSWW
| $141 | ﹤0.01% |
27,090
-4,743
| -15% | -$69 |
2024 Q1
3 quarters
|
|
14337
PUT
Focus Universal
FCUV
$3.08M
| $140 | ﹤0.01% |
1
-4
| -80% | -$409 |
2024 Q3
1 quarter
|
|
14338
Fresenius Medical Care
FMS
$11.8B
| $136 | ﹤0.01% |
6
-68,329
| -100% | -$1.48M |
2021 Q4
12 quarters
|
|
|
AFMD
14339
PUT
DELISTED
Affimed
AFMD
| $119 | ﹤0.01% |
100
-800
| -89% | -$2.24K |
2023 Q2
6 quarters
|
|
|
BNCWW
14340
BNB Standard Corporation Warrant
BNCWW
| $118 | ﹤0.01% |
11,840
-800
| -6% | -$11 |
2023 Q2
6 quarters
|
|
|
AIFU
14341
PUT
AIFU Inc
AIFU
$60.6M
| – | – |
0
| – | – |
2024 Q2
2 quarters
|
|
|
GBIO
14342
PUT
DELISTED
Generation Bio
GBIO
| $106 | ﹤0.01% |
+10
| New | +$178 |
2024 Q4
0 quarters
|
|
14343
PUT
Urban One Class D
UONEK
$16.5M
| $100 | ﹤0.01% |
+10
| New | +$104 |
2024 Q4
0 quarters
|
|
|
KRON
14344
PUT
DELISTED
Kronos Bio
KRON
| $95 | ﹤0.01% |
100
| – | – |
2024 Q3
1 quarter
|
|
|
CPTNW
14345
DELISTED
Cepton, Inc. Warrant
CPTNW
| $88 | ﹤0.01% |
12,593
+600
| +5% | +$6 |
2023 Q3
5 quarters
|
|
|
STLNW
14346
Starling Oncology Warrant
STLNW
$3.46M
| $87 | ﹤0.01% |
12,383
-5,425
| -30% | -$85 |
2023 Q1
7 quarters
|
|
|
SONDW
14347
DELISTED
Sonder Holdings Inc Warrants
SONDW
| $86 | ﹤0.01% |
14,363
-11,425
| -44% | -$118 |
2023 Q1
7 quarters
|
|
14348
PUT
Orion Energy Systems
OESX
$124M
| $80 | ﹤0.01% |
10
-920
| -99% | -$8.06K |
2024 Q2
2 quarters
|
|
14349
PUT
DarioHealth
DRIO
$63.3M
| $79 | ﹤0.01% |
5
-275
| -98% | -$4.76K |
2021 Q1
15 quarters
|
|
|
YI
14350
PUT
111 Inc
YI
$28.3M
| $62 | ﹤0.01% |
10
-480
| -98% | -$3.74K |
2024 Q1
3 quarters
|
|
Similar funds
Citadel Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, Citadel Advisors held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Citadel Advisors's Q4 2024 filing shows 1,745 new, 6,427 increased, 6,082 reduced and 1,421 closed positions. Its largest new stake was Zoetis: 1,090,499 shares worth $178M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 83% a quarter earlier, followed by Healthcare and Technology.
- Citadel Advisors's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Citadel Advisors added most to Boeing in Q4 2024, an estimated $830M increase.
- Citadel Advisors's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Citadel Advisors fully exited Spotify in Q4 2024, selling an estimated $473M.
- Citadel Advisors's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Citadel Advisors opened 1,745 new positions and closed 1,421 in Q4 2024.
- Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.